BlueWind Medical Celebrates Two-Year Results of Revi® System
In an exciting development for those suffering from urgency urinary incontinence (UUI), BlueWind Medical, Ltd., has recently published remarkable two-year findings from its pivotal OASIS study. The company's innovative Revi® System has shown exceptional durability in its results, marking a significant advancement in the treatment of urinary incontinence.
Overview of the OASIS Study
The OASIS study comprised a rigorous assessment of 151 adult women, with an average age of 58.8 years, suffering from the challenges of UUI. This prospective, multicenter, single-arm clinical trial was designed to evaluate the efficacy and safety of the Revi® System. The study primarily focused on how well the device alleviated symptoms associated with UUI in patients diagnosed with overactive bladder-wet syndrome (OAB-wet).
Key Findings from Two-Year Analysis
After two years of observation, the findings unveiled substantial evidence supporting the Revi® System's efficacy and safety. The results highlighted that the majority of participants experienced significant reductions in UUI episodes and enjoyed a favorable reaction to their treatment. Specifically, 79% of participants reported at least a 50% reduction in their UUI episodes, while 56% observed an impressive 75% decrease. These statistics underscore the system's capability to deliver meaningful relief and improve the participants' quality of life.
Patient Satisfaction and Therapy Adjustments
With an astounding 97% of participants feeling satisfied with the treatment, the Revi System demonstrated its patient-centric approach, allowing for flexibility in treatment intervals. In the second year, patients averaged at least one treatment session on eight out of ten days, with individualized approaches tailored to their symptom needs. This adaptability sets Revi apart from other treatment options, enabling healthcare providers to customize treatment plans effectively.
The Safety Profile of Revi® System
Revi’s durability isn’t just in efficacy; it also boasts an enviable safety record. The OASIS study indicated that there were no serious adverse events related to the device or the procedure over the two years. With no instances of device migration or necessary revisions, patients can enjoy a worry-free treatment experience, further reinforcing the value of the Revi System in clinical practice.
Expert Insights on Revi® System
Dr. John Heesakkers, a respected figure in urology, emphasized the significant advantages of the Revi® System, pointing out its capacity for personalized treatment. He remarked, "What sets Revi apart is its patient centricity. The system allows patients to tailor treatment intervals to their symptoms and providers to individualize treatment plans to each patient." His insights reflect the growing trend towards personalized medicine in managing conditions like UUI.
Emerging Demand for Non-Pharmacological Options
In light of rising concerns surrounding the use of anticholinergic drugs and their link to cognitive risks, there’s an urgent push for alternative treatment options that avoid medications. As the first implantable tibial neuromodulation device approved for patients without requiring prior conservative therapy failures, Revi presents an effective and safe alternative for managing UUI.
Commitment to Advancing Treatment
Roger Dmochowski, M.D., who serves as the Chief Medical Advisor at BlueWind Medical, expressed enthusiasm regarding the long-term outcomes demonstrated in the OASIS study. "The two-year study results affirm the Revi System’s significant impact in improving OAB and UUI symptoms and underscore its innovation and effectiveness as a minimally invasive neuromodulation option," he stated. BlueWind's commitment continues to focus on enhancing treatment modalities for individuals struggling with UUI, aiming for improved patient quality of life.
About BlueWind Medical Ltd.
BlueWind Medical remains dedicated to transforming neuromodulation therapy by developing innovative technology tailored to patient needs. With a strong focus on addressing urge urinary incontinence, their Revi® System stands as a pioneering option in minimally invasive therapy options. This commitment demonstrates BlueWind's priority in elevating patients' well-being and providing effective solutions in the face of significant health challenges.
Frequently Asked Questions
What is the Revi® System?
The Revi® System is an innovative tibial neuromodulation device designed to treat urgency urinary incontinence, providing a patient-centric approach to therapy.
What were the results of the OASIS study?
The OASIS study revealed durable effectiveness, with significant reductions in UUI episodes and high patient satisfaction over two years.
Why is the Revi® System considered innovative?
It is the first implantable neuromodulation device approved for UUI that does not require prior conservative therapy failures, offering a flexible and individualized treatment approach.
What safety concerns are associated with the Revi® System?
The safety profile of the Revi® System is robust, with no serious adverse events, device migration, or revisions reported in the OASIS study.
How does the Revi® System support patient autonomy?
The system allows for tailored treatment schedules and individualization, empowering patients to manage their symptoms effectively.
